Serialisation, Aggregation and Authentication - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Serialisation, Aggregation and Authentication


Pharmaceutical Technology Europe
Volume 26, Issue 8, pp. 42
PharmTech Europe 25th Anniversary
DSGpro/Getty Images;
Art direction: Dan Ward

Packaging Provides Safety and Security

Packaging machinery suppliers describe how changes in regulations have driven developments in packaging and look ahead to coming challenges.

Serialisation is among the major trends and future challenges for the pharmaceutical industry. Growing internet sales, outsourcing of production and more complex supply chains require at least national, if not international, legislation to secure pharmaceutical products and, most importantly, to protect patients from counterfeited medicines. Currently, new guidance and legislation are being developed and implemented by numerous countries, such as Argentina, China and Brazil, whose health surveillance agency, ANVISA, adopted a new resolution at the end of 2013.

The United States Food and Drug Administration (FDA) requires pharmaceutical producers to apply a standard numerical identification (SNI) to the packaging of all prescription drugs in a step-by-step approach beginning in 2017. The European Union’s Falsified Medicines Directive (2011/62/EU) also stipulates uniquely coded, serialised packs for almost all prescription drugs. Moreover, the EU has defined a second layer of security to be provided by tamper-proof closures that indicate whether a package has been previously opened or tampered with.

Pharmaceutical Technology Europe
25th Anniversary Issue


Related Content

Protecting Drug Safety

Pharmaceutical manufacturers will be—and are already—facing enormous challenges to implement the respective regulations within the given timeframe. And this implementation is not going to be an easy task. Most companies must develop and apply a global strategy for the consistent serial-number assignment, management and storage on all levels—from devices, line processes and line management to production and enterprise control. Such solutions must be compatible with in-house processes, such as manufacturing execution systems, which in turn require the adaptation of highly demanding packaging processes.

These solutions must be compatible with existing line concepts, and they must be extendable to all possible aggregation levels, including bundling, shipping cartons and pallets. The safest approach undoubtedly consists in a multilayer machine and software concept, which should take all requirements into account and combine all necessary processes in one modular, yet complete system that complies with the industry’s demand for consistent and high-quality operations and with patients’ demands for higher safety.

Johannes Rauschnabel
Johannes Rauschnabel

About the Author
Johannes Rauschnabel, PhD, is chief pharma expert at Bosch Packaging Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here